FABP7

Summary

FABP7 (fatty acid binding protein 7, HGNC:3562) is a protein-coding gene on chromosome 6q22.31, encoding Fatty acid-binding protein, brain (O15540). B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development.

The gene encodes a small, highly conserved cytoplasmic protein that bind long-chain fatty acids and other hydrophobic ligands. The encoded protein is important in the establishment of the radial glial fiber in the developing brain. Alternative splicing and promoter usage results in multiple transcript variants encoding different isoforms. Pseudogenes of this gene are found on multiple chromosomes.

Source: NCBI Gene 2173 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 19 total
• Druggable target: yes
• MANE Select transcript: NM_001446

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3562
Approved symbol	FABP7
Name	fatty acid binding protein 7
Location	6q22.31
Locus type	gene with protein product
Status	Approved
Aliases	B-FABP, BLBP
Ensembl gene	ENSG00000164434
Ensembl biotype	protein_coding
OMIM	602965
Entrez	2173

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000356535, ENST00000368444

RefSeq mRNA: 3 — MANE Select: NM_001446 NM_001319039, NM_001319041, NM_001446

CCDS: CCDS5127, CCDS83121

Canonical transcript exons

ENST00000368444 — 4 exons

Exon	Start	End
ENSE00001084348	122780291	122780463
ENSE00001357868	122781093	122781194
ENSE00001447146	122783717	122784074
ENSE00001447148	122779716	122779867

Expression profiles

Bgee: expression breadth ubiquitous, 211 present calls, max score 99.97.

FANTOM5 (CAGE): breadth broad, TPM avg 28.6750 / max 4689.1821, expressed in 344 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69537	24.8656	322
69535	2.5862	289
69536	1.0876	198
69538	0.1355	48

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	99.97	gold quality
ganglionic eminence	UBERON:0004023	99.87	gold quality
cortical plate	UBERON:0005343	99.58	gold quality
cerebellar vermis	UBERON:0004720	99.21	gold quality
dorsal root ganglion	UBERON:0000044	99.20	gold quality
upper leg skin	UBERON:0004262	99.16	gold quality
cerebellar cortex	UBERON:0002129	99.02	gold quality
cerebellum	UBERON:0002037	99.01	gold quality
cerebellar hemisphere	UBERON:0002245	99.01	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.87	gold quality
paraflocculus	UBERON:0005351	98.81	gold quality
amygdala	UBERON:0001876	98.16	gold quality
mammalian vulva	UBERON:0000997	97.67	gold quality
temporal lobe	UBERON:0001871	97.57	gold quality
diaphragm	UBERON:0001103	97.47	gold quality
trigeminal ganglion	UBERON:0001675	97.40	gold quality
cingulate cortex	UBERON:0003027	97.20	gold quality
anterior cingulate cortex	UBERON:0009835	97.19	gold quality
entorhinal cortex	UBERON:0002728	97.06	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.73	gold quality
right frontal lobe	UBERON:0002810	96.62	gold quality
Ammon’s horn	UBERON:0001954	96.41	gold quality
cerebral cortex	UBERON:0000956	96.22	gold quality
pons	UBERON:0000988	96.14	gold quality
frontal pole	UBERON:0002795	95.93	gold quality
hypothalamus	UBERON:0001898	95.86	gold quality
neocortex	UBERON:0001950	95.81	gold quality
frontal cortex	UBERON:0001870	95.64	gold quality
nucleus accumbens	UBERON:0001882	95.49	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	5700.30
E-HCAD-5	yes	4733.43
E-MTAB-9435	yes	4461.20
E-HCAD-56	yes	4007.02
E-MTAB-8894	yes	3696.28
E-MTAB-11121	yes	3619.36
E-GEOD-93593	yes	2471.02
E-MTAB-7316	yes	2078.69
E-GEOD-75140	yes	1183.31
E-GEOD-75688	yes	715.00
E-GEOD-137537	yes	41.29
E-GEOD-84465	yes	23.53
E-ANND-3	no	2.26

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KLF7, NFIB, NFIC, NOTCH1, NR2E1, NR2F1, PAX3, PAX6, PKNOX1, POU3F1, POU3F2, RBPJ, SOX2

miRNA regulators (miRDB)

11 targeting FABP7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-4329	97.68	66.26	1003
HSA-MIR-6500-3P	97.42	67.20	867

Literature-anchored findings (GeneRIF, showing 40)

• overall structure exhibits the typical backbone conformation described for other members of the FABP family, consisting of antiparallel beta-strands that form two almost orthogonal beta-sheets, a helix-turn-helix motif and a short N-terminal helical loop (PMID:12479569)
• BLBP, stimulated by Ras-independent pathways, regulates Schwann cell-axon interactions in normal peripheral nerve and peripheral nerve tumors. (PMID:12612091)
• Overexpression of FABP7 in Down syndrome fetal brains. (PMID:12771203)
• Functional analysis in mice. (PMID:12975368)
• data indicate that MRG is a mediator of the differentiating effects of pregnancy on breast epithelium (PMID:12975368)
• Increases tumor cell motility in vitro and over-expression is associated with poor prognosis in glioblastoma patients (PMID:15827123)
• A possible mechanism for the association of nuclear FABP7 & poor prognosis of glioblastoma multiforme is that nuclear FABP7 may be induced by EGFR activation to promote migration of GBM tumor cells. (PMID:16623952)
• relation between FABP7, astrocytic features, invasion and poor prognosis and suggests that EGFR amplification is associated with nuclear translocation of FABP7. (PMID:17415524)
• There were not significant difference in B-FABP expression between ductal infiltrating carcinoma and benign tissue in human breast cancer. (PMID:17428383)
• Upregulation of FABP7 in renal cell carcinoma was confirmed by quantitative RT-PCR. (PMID:17646957)
• B-FABP expression in malignant glioma cells is accompanied by the appearance of radial glial-like properties, as well as reduced transformation. B-FABP depletion results in decreased migration, reduction in cell processes, & a more transformed phenotype. (PMID:17898869)
• Decreased expression of FABP-7 in fetal cystic adenomatoid malformation (CCAM) suggests FABP-7 may have a role in pulmonary development and in the pathogenesis of CCAM. (PMID:18391847)
• Both in vitro Reelin treatment and overexpression of Notch-1 intracellular domain induced BLBP expression and a radial glial phenotype in an immortalized human neural progenitor cell line, isolated from the cortex of 14 weeks old fetus (PMID:18593473)
• High expression of FABP7 is associated with melanoma (PMID:18826602)
• NFI family of transcription factors plays a key role in the regulation of both the B-FABP and GFAP genes in malignant glioma cells. (PMID:19540848)
• brain-expressed fatty-acid binding protein (FABP) genes 3, 5 and 7 may have roles in schizophrenia and bipolar disorder (PMID:19554614)
• FABP7 may function as a tumor progression gene in melanoma (PMID:19587692)
• We have identified a novel subgroup of basal phenotype (BP) class of breast cancers showing FABP7 expression that have significantly better clinical outcome. (PMID:19590950)
• this study is the first to demonstrate overexpression of FABP-7 in triple-negative breast cancers (PMID:19608352)
• While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue (PMID:19622156)
• Studies indicate that three of the ten mammalian FABPs identified to date (FABP3, FABP5, FABP7) are expressed in the brain. (PMID:20563994)
• High FABP7 is associated with malignant glioma. (PMID:20834042)
• In contrast to heart-type FABP, serum levels of brain-type FABP are elevated in a significant proportion of patients with various neurodegenerative diseases. (PMID:21143341)
• BFABP is involved in cell proliferation and migration of human renal carcinoma cells. (PMID:21399875)
• expression of BLBP in activated astrocytes negatively correlates with disease duration and in parallel with remyelination failure (PMID:21620951)
• Data show that three putative FABP7 promoter regions drive reporter gene expression in renal cell carcinoma cell lines, but not in the HEK293 cell line. (PMID:21771320)
• A fatty acid-binding protein 7/RXRbeta pathway enhances survival and proliferation in triple-negative breast cancer. (PMID:22322885)
• Considerable heterogeneity in expression patterns of FABP7 within breast cancer elates to differences in biological behaviour especially in basal-like breast cancer. (PMID:22562177)
• These data provide the first evidence of direct transactivation of the FABP7 proximal promoter by PAX6 and suggest a synergistic mechanism for PAX6 and other co-factor(s) in regulating FABP7 expression in malignant glioma. (PMID:22583899)
• identified its binding target by proteomic analysis as fatty acid binding protein 7 (FABP7), also known as brain lipid binding protein) which is highly expressed in neural stem cells and localized in the cytoplasm (PMID:22689954)
• Report feasibility of detecting B-FABP as biomarker for ischemic brain damage during extrcorporeal circulation in coronary artery bypass grafting patients. (PMID:23020859)
• FABP7 is almost exclusively expressed in neurospheres and not in the adherent cells, derived from the same glioblastoma tumor. (PMID:23284888)
• FABP7 and FABP5 are differentially expressed in oligodendrocyte lineage cells and regulate their proliferation and/or differentiation. (PMID:24114376)
• Our data introduces FABP7 as a marker for glioma stem cells and further highlights its possible significance for glioma diagnosis and treatment. (PMID:24274717)
• These results suggest an important role of Rev-erbalpha and Fabp7 in adult neurogenesis. (PMID:24932636)
• The mRNA/protein expressions of FABP7 was lower in the stenotic colon segment tissue than in the normal colon segment tissue of Hirschsrung disease patients. (PMID:24966941)
• The frameshift and missense mutations in FABP3, FABP5, and FABP7 genes have been identified in schizophrenia and autism spectrum disorder in humans and in mouse behavioral studies. (PMID:25027319)
• identified 98 transposable element-FABP7 gene chimeric transcripts that were exclusively expressed in primary diffuse large B-cell lymphoma (DLBCL) cases and confirmed several in DLBCL-derived cell lines (PMID:25114248)
• FABP7 is overexpressed in clear cell renal cell carcinoma and promotes cell growth by the activation of ERK and Stat3 signaling pathways (PMID:25192834)
• FABP7 and HMGCS2 may have roles in apocrine differentiation categorizing apocrine carcinoma of the breast (PMID:25389781)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	fabp7a	ENSDARG00000007697
danio_rerio	fabp7b	ENSDARG00000034650
mus_musculus	Fabp7	ENSMUSG00000019874
rattus_norvegicus	Fabp7	ENSRNOG00000000814
caenorhabditis_elegans		WBGENE00002259
caenorhabditis_elegans		WBGENE00002260

Paralogs (15): RBP2 (ENSG00000114113), RBP1 (ENSG00000114115), FABP3 (ENSG00000121769), RBP5 (ENSG00000139194), CRABP2 (ENSG00000143320), FABP2 (ENSG00000145384), PMP2 (ENSG00000147588), RBP7 (ENSG00000162444), FABP1 (ENSG00000163586), FABP5 (ENSG00000164687), CRABP1 (ENSG00000166426), FABP6 (ENSG00000170231), FABP4 (ENSG00000170323), FABP12 (ENSG00000197416), FABP9 (ENSG00000205186)

Protein

Protein identifiers

Fatty acid-binding protein, brain — O15540 (reviewed: O15540)

Alternative names: Brain lipid-binding protein, Brain-type fatty acid-binding protein, Fatty acid-binding protein 7, Mammary-derived growth inhibitor related

All UniProt accessions (1): O15540

UniProt curated annotations — full annotation on UniProt →

Function. B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development. It is required for the establishment of the radial glial fiber system in developing brain, a system that is necessary for the migration of immature neurons to establish cortical layers.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in brain and other neural tissues.

Domain organisation. Forms a beta-barrel structure that accommodates the hydrophobic ligand in its interior.

Similarity. Belongs to the calycin superfamily. Fatty-acid binding protein (FABP) family.

Isoforms (2)

UniProt ID	Names	Canonical?
O15540-1	1	yes
O15540-2	2

RefSeq proteins (3): NP_001305968, NP_001305970, NP_001437* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000463	Fatty_acid-bd	Domain
IPR000566	Lipocln_cytosolic_FA-bd_dom	Domain
IPR012674	Calycin	Homologous_superfamily
IPR031259	ILBP	Family

Pfam: PF00061

UniProt features (22 total): strand 10, helix 3, sequence conflict 2, initiator methionine 1, chain 1, turn 1, binding site 1, modified residue 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
6L9O	X-RAY DIFFRACTION	1.42
7E25	X-RAY DIFFRACTION	1.6
5URA	X-RAY DIFFRACTION	1.85
9NIU	X-RAY DIFFRACTION	1.9
1FDQ	X-RAY DIFFRACTION	2.1
8IVF	X-RAY DIFFRACTION	2.6
8IVL	X-RAY DIFFRACTION	2.7
1FE3	X-RAY DIFFRACTION	2.8
1JJX	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15540-F1	96.41	0.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 127–129

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-163560	Triglyceride catabolism
R-HSA-9013508	NOTCH3 Intracellular Domain Regulates Transcription

MSigDB gene sets: 175 (showing top): REACTOME_TRIGLYCERIDE_CATABOLISM, REACTOME_SIGNALING_BY_NOTCH, LEE_NEURAL_CREST_STEM_CELL_DN, SHEPARD_BMYB_MORPHOLINO_DN, GOBP_ORGANIC_ACID_TRANSPORT, MODULE_66, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, MODULE_205, FOSTER_TOLERANT_MACROPHAGE_DN, KEGG_PPAR_SIGNALING_PATHWAY, GOBP_ORGANIC_ANION_TRANSPORT, SANSOM_APC_TARGETS_DN, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT, KIM_GASTRIC_CANCER_CHEMOSENSITIVITY, VANTVEER_BREAST_CANCER_ESR1_DN

GO Biological Process (4): nervous system development (GO:0007399), negative regulation of cell population proliferation (GO:0008285), fatty acid transport (GO:0015908), epithelial cell proliferation (GO:0050673)

GO Molecular Function (3): fatty acid binding (GO:0005504), lipid binding (GO:0008289), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Triglyceride metabolism	1
Signaling by NOTCH3	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell population proliferation	2
binding	2
cellular anatomical structure	2
system development	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
lipid transport	1
monocarboxylic acid transport	1
lipid binding	1
monocarboxylic acid binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1892 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FABP7	FAAH	O00519	839
FABP7	SLC1A3	P43003	715
FABP7	NES	P48681	715
FABP7	GFAP	P14136	697
FABP7	HES5	Q5TA89	680
FABP7	NEUROG2	Q9H2A3	667
FABP7	GOT2	P00505	666
FABP7	PAX6	P26367	659
FABP7	S100B	P04271	657
FABP7	PROM1	O43490	638
FABP7	ELAVL3	Q14576	630
FABP7	OLIG2	Q13516	613
FABP7	SOX2	P48431	604
FABP7	RBFOX3	A6NFN3	599
FABP7	DCX	O43602	585

IntAct

37 interactions, top by confidence:

A	B	Type	Score
FABP7	DMWD	psi-mi:“MI:0915”(physical association)	0.560
FABP7		psi-mi:“MI:0915”(physical association)	0.560
GPR37	FABP7	psi-mi:“MI:0915”(physical association)	0.560
GRN	FABP7	psi-mi:“MI:0915”(physical association)	0.560
FABP7	GRN	psi-mi:“MI:0915”(physical association)	0.560
FABP7	PMP22	psi-mi:“MI:0915”(physical association)	0.560
FABP7	WFS1	psi-mi:“MI:0915”(physical association)	0.560
FABP7	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
FABP7	RNF11	psi-mi:“MI:0915”(physical association)	0.560
FABP7	SPRED1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (17): AKR1B1 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), FABP7 (Co-fractionation), PPIL3 (Co-fractionation), FABP7 (Two-hybrid), FABP7 (Affinity Capture-MS), FABP7 (Affinity Capture-MS), FABP7 (Affinity Capture-MS), FABP7 (Affinity Capture-MS), FABP7 (Affinity Capture-MS)

ESM2 similar proteins: A0A0K0MJ13, A0A0K0MJN3, A6YLM6, C4N147, O01812, O01814, O02772, O08716, O13008, O15540, O45035, O97788, P02689, P02690, P02691, P04117, P05413, P06768, P07483, P0C6G6, P10790, P11404, P15090, P24526, P29498, P41496, P41509, P48035, P50120, P50121, P51880, P55051, P55052, P55053, P70623, P80049, P86412, Q01469, Q02970, Q05423

Diamond homologs: A0A0K0MJ13, A0A0K0MJN3, A6NFH5, A6YLM6, A8MUU1, B7SUM8, C4N147, O01812, O01814, O02323, O02324, O02772, O08716, O13008, O15540, O42386, O45035, O76821, O97788, P02689, P02690, P02691, P02694, P02696, P04117, P05413, P06768, P07148, P07483, P09455, P0C6G6, P10790, P11404, P12710, P15090, P22935, P24526, P29373, P29498, P29762

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
NOTCH1	“up-regulates quantity by expression”	FABP7	“transcriptional regulation”
FABP7	“up-regulates quantity”	“Fatty acid”	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

19 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	16
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

483 predictions. Top by Δscore:

Variant	Effect	Δscore
6:122780459:GTAAG:G	donor_gain	1.0000
6:122780463:GGTGA:G	donor_loss	1.0000
6:122780464:G:C	donor_loss	1.0000
6:122781092:GTCT:G	acceptor_gain	1.0000
6:122780464:G:GG	donor_gain	0.9900
6:122781074:A:AG	acceptor_gain	0.9900
6:122781074:ATTTT:A	acceptor_gain	0.9900
6:122781075:T:G	acceptor_gain	0.9900
6:122781081:T:A	acceptor_gain	0.9900
6:122781084:T:TA	acceptor_gain	0.9900
6:122781091:A:AG	acceptor_gain	0.9900
6:122781092:G:GG	acceptor_gain	0.9900
6:122781191:TATGG:T	donor_loss	0.9900
6:122781192:ATGG:A	donor_loss	0.9900
6:122781193:TGGTA:T	donor_loss	0.9900
6:122781194:GGT:G	donor_loss	0.9900
6:122781195:G:T	donor_loss	0.9900
6:122781196:T:A	donor_loss	0.9900
6:122781197:AA:A	donor_loss	0.9900
6:122781078:T:TA	acceptor_gain	0.9800
6:122781091:AGTCT:A	acceptor_gain	0.9800
6:122781092:GT:G	acceptor_gain	0.9800
6:122781092:GTCTG:G	acceptor_gain	0.9800
6:122781198:AGT:A	donor_loss	0.9800
6:122783715:A:AG	acceptor_gain	0.9800
6:122783716:G:GG	acceptor_gain	0.9800
6:122781085:G:A	acceptor_gain	0.9700
6:122781092:GTC:G	acceptor_gain	0.9700
6:122781066:T:G	acceptor_gain	0.9600
6:122781088:CTCA:C	acceptor_loss	0.9600

AlphaMissense

888 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:122780318:G:A	G34E	0.994
6:122780454:A:C	R79S	0.994
6:122780454:A:T	R79S	0.994
6:122783741:G:C	A125P	0.994
6:122780310:G:C	R31S	0.992
6:122780310:G:T	R31S	0.992
6:122780383:A:C	S56R	0.992
6:122780385:C:A	S56R	0.992
6:122780385:C:G	S56R	0.992
6:122780428:T:C	F71L	0.992
6:122780430:T:A	F71L	0.992
6:122780430:T:G	F71L	0.992
6:122779819:T:A	W9R	0.991
6:122779819:T:C	W9R	0.991
6:122779843:T:C	F17L	0.991
6:122779845:T:A	F17L	0.991
6:122779845:T:G	F17L	0.991
6:122783742:C:A	A125D	0.990
6:122779821:G:C	W9C	0.989
6:122779821:G:T	W9C	0.989
6:122780309:G:C	R31T	0.989
6:122779857:G:A	M21I	0.988
6:122779857:G:C	M21I	0.988
6:122779857:G:T	M21I	0.988
6:122780453:G:C	R79T	0.988
6:122781093:T:C	S83P	0.988
6:122781100:T:A	V85D	0.988
6:122783748:G:C	R127P	0.988
6:122780303:C:A	A29D	0.986
6:122780309:G:T	R31M	0.986

dbSNP variants (sampled 300 via entrez): RS1000071668 (6:122780449 G>GATAGAA), RS1000123603 (6:122774503 T>G), RS1000308461 (6:122749176 A>T), RS1000322593 (6:122755473 T>C), RS1000412186 (6:122774845 T>C), RS1000445236 (6:122751500 T>C), RS1000555682 (6:122756793 A>G,T), RS1000686929 (6:122778754 C>T), RS1000725497 (6:122773291 T>C), RS1000786660 (6:122763149 G>A,C), RS1000839342 (6:122761530 G>A), RS1001030626 (6:122761201 T>C), RS1001064165 (6:122750412 T>C), RS1001175666 (6:122762520 C>A,T), RS1001313328 (6:122783989 C>A,T)

Disease associations

OMIM: gene MIM:602965 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004162_26	Carotid plaque burden	2.000000e-06
GCST008246_2	Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers	4.000000e-06
GCST008247_2	Airway obstruction (FEV1/FVC<70%) in never smokers	3.000000e-07
GCST010725_10	Malaria	3.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006501	carotid plaque build
EFO:0003892	pulmonary function measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3826863 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Fatty acid-binding proteins

ChEMBL bioactivities

48 potent at pChembl≥5 of 52 total, top 48 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.70	IC50	20	nM	CHEMBL5567823
6.82	Ki	150	nM	CHEMBL4277947
6.48	Ki	330	nM	CHEMBL4288603
6.46	Ki	350	nM	CHEMBL4287117
6.40	Ki	400	nM	CHEMBL4284051
6.40	Ki	400	nM	CHEMBL4292072
6.40	Ki	400	nM	CHEMBL4289745
6.35	Ki	450	nM	CHEMBL4292072
6.35	Ki	450	nM	CHEMBL4281879
6.30	Ki	500	nM	CHEMBL4290002
6.28	Ki	530	nM	CHEMBL4293131
6.27	Ki	540	nM	CHEMBL4279887
6.27	Ki	540	nM	CHEMBL4293939
6.27	Ki	540	nM	CHEMBL5399759
6.24	Ki	570	nM	CHEMBL5394488
6.20	Ki	630	nM	CHEMBL5430100
6.17	Ki	670	nM	CHEMBL4287414
6.13	Ki	740	nM	CHEMBL4295043
6.11	Ki	780	nM	CHEMBL4291624
6.08	Ki	830	nM	CHEMBL5542476
6.05	Ki	890	nM	CHEMBL4289745
6.03	Ki	940	nM	CHEMBL4283759
6.02	Ki	960	nM	CHEMBL5404205
5.99	Ki	1030	nM	CHEMBL4293382
5.98	Ki	1040	nM	CHEMBL5436742
5.97	Ki	1060	nM	CHEMBL4282121
5.97	Ki	1060	nM	CHEMBL4276753
5.97	Ki	1080	nM	CHEMBL5396730
5.95	Ki	1120	nM	CHEMBL4278244
5.94	Ki	1140	nM	CHEMBL4285313
5.90	Ki	1250	nM	CHEMBL4293553
5.89	Ki	1300	nM	CHEMBL5568424
5.82	Ki	1500	nM	CHEMBL5561112
5.81	Ki	1550	nM	CHEMBL5434176
5.80	Ki	1590	nM	CHEMBL4292332
5.78	Ki	1650	nM	CHEMBL4282959
5.77	Ki	1690	nM	CHEMBL5422779
5.76	Ki	1750	nM	CHEMBL5433914
5.73	Ki	1860	nM	CHEMBL5403530
5.67	Ki	2120	nM	CHEMBL4276759
5.64	Ki	2270	nM	CHEMBL4290535
5.62	Ki	2410	nM	CHEMBL4281708
5.57	Ki	2700	nM	CHEMBL4285544
5.48	Ki	3340	nM	CHEMBL5416088
5.48	Ki	3300	nM	CHEMBL5564420
5.45	Ki	3540	nM	CHEMBL4292323
5.20	Ki	6320	nM	CHEMBL4294220
5.13	Ki	7430	nM	CHEMBL4288922

PubChem BioAssay actives

48 with measured affinity, of 72 total; 44 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[2-[5-(2-chlorophenyl)-1-(4-propan-2-ylphenyl)pyrazol-3-yl]-4-fluorophenoxy]butanoic acid	2082688: Binding affinity to human FABP7 assessed as dissociation constant	ic50	0.0200	uM
trans-(2S,4S)-2,4-diphenyl-3-[(1S,2R)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.1500	uM
trans-(2S,4S)-2,4-diphenyl-3-[(1R,2S)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.3300	uM
trans-(2S,4S)-2,4-diphenyl-3-(2-phenylphenoxy)carbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.3500	uM
trans-(2R,4R)-3-naphthalen-1-yloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2082690: Binding affinity to human FABP7 assessed as inhibition constant	ki	0.4000	uM
trans-(2S,4S)-2,4-bis(2-methoxyphenyl)-3-[(1R,2S)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.4000	uM
3-naphthalen-1-yloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404713: Displacement of NBD-stearate from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) by fluorescence assay	ki	0.4000	uM
trans-(2S,4S)-3-naphthalen-1-yloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.4500	uM
trans-(2S,4S)-3-cyclohexyloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.5000	uM
trans-(2S,4S)-2,4-diphenyl-3-phenylmethoxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.5300	uM
trans-(2S,4S)-3-[2-(2-hydroxyphenyl)phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.5400	uM
trans-(2S,4S)-2,4-diphenyl-3-(2,4,5-trichlorophenoxy)carbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.5400	uM
trans-(2S,4S)-3-[3-(2-oxo-1,3-dihydroindol-6-yl)phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	0.5400	uM
trans-(2S,4S)-3-[3-(1,3-benzodioxol-5-yl)phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	0.5700	uM
trans-(2S,4S)-3-(2-cyano-5-phenylphenoxy)carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	0.6300	uM
trans-(2S,4S)-2,4-bis(2-methoxyphenyl)-3-naphthalen-1-yloxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.6700	uM
trans-(2S,4S)-2,4-diphenyl-3-(3-phenylphenoxy)carbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.7400	uM
trans-(2S,4S)-3-(3-ethynylphenoxy)carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.7800	uM
trans-(2S,4S)-3-[3-(3,6-dihydro-2H-pyran-4-yl)phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2082690: Binding affinity to human FABP7 assessed as inhibition constant	ki	0.8300	uM
trans-(2S,4S)-3-(2-iodophenoxy)carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.9400	uM
trans-(2S,4S)-3-(2-cyano-5-phenylphenoxy)carbonyl-2,4-bis(2-methoxyphenyl)cyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	0.9600	uM
trans-(2S,4S)-3-(5-ethynylnaphthalen-1-yl)oxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.0300	uM
trans-(2S,4S)-3-[3-(1,3-benzodioxol-5-yl)phenoxy]carbonyl-2,4-bis(2-methoxyphenyl)cyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	1.0400	uM
trans-(2S,4S)-3-[3-[1-[2-[2-(2-ethoxyethoxy)ethoxy]ethyl]triazol-4-yl]phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.0600	uM
trans-(2S,4S)-2,4-bis(4-hydroxyphenyl)-3-naphthalen-1-yloxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.0600	uM
trans-(2R,4R)-3-[[3-(1,3-benzodioxol-5-yl)phenyl]carbamoyl]-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	1.0800	uM
trans-(2S,4S)-3-(6-acetamidonaphthalen-1-yl)oxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.1200	uM
trans-(2S,4S)-3-[(4-methoxyphenyl)methoxycarbonyl]-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.1400	uM
trans-(2S,4S)-3-[(4-bromophenyl)methoxycarbonyl]-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.2500	uM
trans-(2R,4R)-3-naphthalen-2-yloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2082685: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based analysis	ki	1.3000	uM
trans-(2S,4S)-3-(naphthalen-1-ylcarbamoyl)-2,4-diphenylcyclobutane-1-carboxylic acid	2082685: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based analysis	ki	1.5000	uM
trans-(2R,4R)-3-[[3-(2-oxo-1,3-dihydroindol-6-yl)phenyl]carbamoyl]-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	1.5500	uM
trans-(2S,4S)-2,4-diphenyl-3-(2,2,2-trifluoroethoxycarbonyl)cyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.5900	uM
trans-(2S,4S)-3-[(4-fluorophenyl)methoxycarbonyl]-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.6500	uM
trans-(2R,4R)-3-[(2-cyano-5-phenylphenyl)carbamoyl]-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	1.6900	uM
trans-(2S,4S)-3-[2-cyano-5-(3,6-dihydro-2H-pyran-4-yl)phenoxy]carbonyl-2,4-diphenylcyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	1.7500	uM
trans-(2S,4S)-2,4-bis(4-hydroxy-3-methoxyphenyl)-3-naphthalen-1-yloxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	2.1200	uM
trans-(2S,4S)-2,4-diphenyl-3-(4-phenylphenoxy)carbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	2.2700	uM
trans-(2S,4S)-3-(2,3-dihydro-1H-inden-2-yloxycarbonyl)-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	2.4100	uM
trans-(2S,4S)-3-(9H-fluoren-9-ylmethoxycarbonyl)-2,4-diphenylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	2.7000	uM
1-N,3-N-dinaphthalen-1-yl-2,4-diphenylcyclobutane-1,3-dicarboxamide	2082685: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based analysis	ki	3.3000	uM
trans-(2S,4S)-2,4-bis(2-methoxyphenyl)-3-[(2-phenylphenyl)methoxycarbonyl]cyclobutane-1-carboxylic acid	2014899: Displacement of fluorescent probe ANS from FABP7 (unknown origin) assessed as inhibition constant by fluorescence based microplate reader analysis	ki	3.3400	uM
trans-(2S,4S)-2,4-bis(2-chlorophenyl)-3-(9H-fluoren-9-ylmethoxycarbonyl)cyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	3.5400	uM
trans-(2S,4S)-2,4-bis(2,6-dichlorophenyl)-3-[(1R,2S)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404707: Displacement of ANS from recombinant human N-terminal His-tagged FABP7 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	6.3200	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	7
methylmercuric chloride	decreases expression, affects cotreatment	5
trichostatin A	affects cotreatment, increases expression	3
Tretinoin	increases expression, decreases expression	3
bisphenol A	decreases expression, increases expression	2
sodium arsenite	affects methylation, decreases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, decreases expression, affects cotreatment	2
Resveratrol	increases expression, affects cotreatment, decreases expression	2
Vorinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
glycidyl methacrylate	decreases expression	1
terbufos	increases methylation	1
2-palmitoylglycerol	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
LDN 193189	affects cotreatment, increases expression	1
FV-429 compound	affects cotreatment, decreases reaction, increases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	decreases expression	1
Alitretinoin	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Carbamazepine	affects expression	1
Chenodeoxycholic Acid	decreases expression	1
Cytarabine	increases expression	1
Docosahexaenoic Acids	decreases response to substance	1
Fonofos	increases methylation	1
Fluorouracil	decreases expression	1
Mercury	increases expression	1
Nickel	decreases expression	1
Oxygen	decreases reaction, increases expression, affects cotreatment	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3828898	Binding	Displacement of 1,8-ANS from His6-tagged FABP7 (unknown origin) expressed in Escherichia coli BL21(DE3) cells at 25 uM by fluorescence assay relative to control	The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.